Amylyx Passed The Hat

 

U.S. stocks fell Tuesday. The July CPI report last week is still setting the tone, with rates and inflation risk keeping the Street defensive. Chip stocks fell a whopping 5%, tech leading the sector declines for the day.  Yields on longer dated bonds, like the U.S. 30 year note, surged to their highest since 2007 this week, and other global bills followed. The market is pricing in turmoil and inflation, according to Justin Onuekwusi, a CIO at St. James Place reached by Bloomberg. The 10-year yield is about 1% point higher than the FOMC’s Federal Funds Rate goal, a sign to some that ‘bond vigilantes’ want rates to climb.  This week is retail earnings week, but Home Depot's beat Tuesday morning did little to inspire confidence. The stock fell slightly after a 4% EPS beat.  Retail on Stocks was looking past the declining chip names, and instead still chasing strength in biotechs and fan favorite long shots.  On the blue-chip board, the defensives did the heavy lifting — $LLY +3.6% and $JNJ +3.3% — while the chip complex dragged, with $MU -7.0% and $INTC -6.6%.  Today’s Briefing: Powered by Stocktwits Community API. After the Bell: Amylyx’s Phase 3 win triggered a 64% rally and a proposed $350M offering.  Stocks: Klarna’s earnings beat collided with weaker guidance and a 22.8% selloff.  What's Trending Now on Stocks

AFTER THE BELL Amylyx Passed The Hat

Amylyx, a clinical-stage biotech, said Tuesday that avexitide cut serious low-blood-sugar events by 55% in a Phase 3 trial, clearing the way for an FDA application by year-end. After shares surged, the company proposed a $350M stock offering to fund pre-commercial work, research, and development. The offering did little to stop the good news.

The RIP:  $AMLX ( ▲ 63.84% )  surged 63.8% to $35.11 on 23.9M shares, 19.9x recent pace. LUCIDITY enrolled 78 adults, and avexitide cut Level 2 and Level 3 events 55% over 16 weeks. Amylyx proposed a $350M offering after the close; June 30 cash was $250.8M.

Holders got the result they needed, a 55% reduction and every secondary endpoint, followed immediately by a $350M dilution spreadsheet. Amylyx plans to file with the FDA by year-end and is preparing for a possible 2027 launch, making regulatory acceptance the next checkpoint. The Stocktwits room has already skipped from $60 to $100 price targets, because one successful trial apparently also cures patience.

The Community Read: The $AMLX room is bullish after LUCIDITY, inspect the post-rally price targets ->

STOCKS Klarna Pays For Guidance

Klarna, the buy-now-pay-later company, delivered a surprise profit Tuesday, then watched investors bill it for weaker German volumes and lower full-year GMV and revenue guidance. Revenue and transaction margins grew, but the guide was the only line the market wanted to finance.

The RIP: $KLAR fell 22.8% to $15.06 on 34.4M shares, 7.2x recent pace. Adjusted EPS was $0.01 vs. a $0.04 loss expected; revenue was $1.04B vs. $993.79M. Revenue rose 27%, transaction margin dollars climbed 42%, and net income reached $4M.

Transaction margin dollars grew 42%, but lower GMV and revenue guidance told holders that German weakness could shrink the pie faster than margins improve. Stocktwits bulls argued that Apple and Walmart distribution can offset the missing volume. If U.S. growth cannot keep transaction margins rising, Tuesday’s dip-buying math loses its favorite alibi.

The Community Read: The $KLAR room stayed bullish after the guide cut, test the overreaction case ->

POPS & DROPS Trending Now

$EYPT +14% | EyePoint: The rebound put one trial back on trial

9.4K WATCHERS · EXTREMELY BULLISH · EXTREMELY HIGH ACTIVITY

EyePoint rebounded 14% a session after its LUGANO Phase 3 miss erased nearly 67%, even as Citi and Chardan slashed price targets Tuesday. The extremely bullish room is treating the anomalous-patient explanation and upcoming LUCIA readout as a second chance, but the regulatory path remains the unresolved part.

$TGT +1% | Target: The turnaround faces a higher bar Wednesday

50.1K WATCHERS · EXTREMELY BULLISH · HIGH ACTIVITY

Target edged higher before Wednesday’s Q2 report, with shares already up more than 50% this year after investors embraced its turnaround. The extremely bullish room is debating whether sales and traffic can clear a much higher bar, especially as consumer uncertainty collides with the retailer’s beauty reset.

$WULF -11% | TeraWulf: The deal could not outrun the bond market

31K WATCHERS · NEUTRAL · NORMAL ACTIVITY

TeraWulf fell 11% as rising Treasury yields punished capital-hungry AI infrastructure names and renewed questions about how much growth is already priced into its Anthropic-backed buildout. The neutral room is split between long-term power-infrastructure believers and traders frustrated that the headline deal has not protected the stock from the group unwind.

$WYFI -32% | WhiteFiber: The financing bill arrived after the close

7.1K WATCHERS · BULLISH · HIGH ACTIVITY

WhiteFiber sank after announcing a proposed $250M private placement of convertible senior notes, adding financing risk just as the data-center operator expands its North Carolina footprint. The bullish stream now has to decide whether the capital funds valuable capacity or hands new investors too much of the upside.

WHAT’S ON DECK Tomorrow’s Top Things

Macro: Federal Open Market Committee (FOMC) meeting minutes (2:00 PM ET).  Pre-Market Earnings: $TGT Target Corp, $LOW Lowe`s Cos., Inc., $NNOX Nano X Imaging Ltd, $ZIM Zim Integrated Shipping Services Ltd, $WB Weibo Corp - ADR, +5 more.  After-Market Earnings: $BULL Webull Corp. - Ordinary Shares - Class A, $WOLF Wolfspeed Inc - Ordinary Shares (New), $COTY Coty Inc - Ordinary Shares - Class A, $BILL BILL Holdings Inc, $AIFC AI Financial Corp., +1 more.